Literature DB >> 10097917

Impaired fasting glucose or impaired glucose tolerance. What best predicts future diabetes in Mauritius?

J E Shaw1, P Z Zimmet, M de Courten, G K Dowse, P Chitson, H Gareeboo, F Hemraj, D Fareed, J Tuomilehto, K G Alberti.   

Abstract

OBJECTIVE: To determine if impaired fasting glucose (IFG; fasting plasma glucose level 6.1-6.9 mmol/l) can predict future type 2 diabetes as accurately as does impaired glucose tolerance (IGT; 2-h plasma glucose level 7.8-11.0 mmol/l). RESEARCH DESIGN AND METHODS: A longitudinal population-based study was performed with surveys in 1987 and 1992 on the island of Mauritius, assessing diabetes status by the oral glucose tolerance test. A total of 3,717 subjects took part in both surveys. Of these subjects, 3,229 were not diabetic in 1987 and formed the basis of this study.
RESULTS: At baseline, there were 607 subjects with IGT and 266 subjects with IFG. There were 297 subjects who developed diabetes by 1992. For predicting progression to type 2 diabetes, the sensitivity, specificity, and positive predictive values were 26, 94, and 29% for IFG and 50, 84, and 24% for IGT, respectively. Only 26% of subjects that progressed to type 2 diabetes were predicted by their IFG values, but a further 35% could be identified by also considering IGT. The sensitivities were 24% for IFG and 37% for IGT in men and 26% for IFG and 66% for IGT in women, respectively.
CONCLUSIONS: These data demonstrate the higher sensitivity of IGT over IFG for predicting progression to type 2 diabetes. Screening by the criteria for IFG alone would identify fewer people who subsequently progress to type 2 diabetes than would the oral glucose tolerance test.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10097917     DOI: 10.2337/diacare.22.3.399

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  79 in total

Review 1.  The major diabetes prevention trials.

Authors:  Jaakko Tuomilehto; Jaana Lindström
Journal:  Curr Diab Rep       Date:  2003-04       Impact factor: 4.810

Review 2.  Lifestyle interventions in preventing new type 2 diabetes in Asian populations.

Authors:  Pietro Amedeo Modesti; Giorgio Galanti; Piergiuseppe Cala'; Maria Calabrese
Journal:  Intern Emerg Med       Date:  2015-10-16       Impact factor: 3.397

3.  Glucevia Fraxinus excelsior Extract Effectively Controls Blood Glucose Levels in Randomized, Controlled Trial.

Authors:  Thomas Ughetto
Journal:  Integr Med (Encinitas)       Date:  2014-08

Review 4.  Physical disability in the elderly with diabetes: epidemiology and mechanisms.

Authors:  Lara Bianchi; Giovanni Zuliani; Stefano Volpato
Journal:  Curr Diab Rep       Date:  2013-12       Impact factor: 4.810

5.  Progression from newly acquired impaired fasting glusose to type 2 diabetes.

Authors:  Gregory A Nichols; Teresa A Hillier; Jonathan B Brown
Journal:  Diabetes Care       Date:  2007-02       Impact factor: 19.112

6.  Screening for diabetes in women with polycystic ovary syndrome.

Authors:  David C W Lau
Journal:  CMAJ       Date:  2007-03-27       Impact factor: 8.262

7.  Effect of Tang No.1 granule (1) in treating patients with impaired glucose tolerance.

Authors:  Yan WEI; Yu-zhi HONG; Xun YE
Journal:  Chin J Integr Med       Date:  2008-12-12       Impact factor: 1.978

Review 8.  Impaired fasting glucose as a treatment target in diabetes management.

Authors:  Rene A Oliveros; Adrienne S Zion; Yelena Rosenberg; Carrie Lynn Selvaraj; Robert Chilton
Journal:  Curr Cardiol Rep       Date:  2009-11       Impact factor: 2.931

Review 9.  Progression from IGT to type 2 diabetes mellitus: the central role of impaired early insulin secretion.

Authors:  Richard E Pratley; Christian Weyer
Journal:  Curr Diab Rep       Date:  2002-06       Impact factor: 4.810

10.  Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study.

Authors:  Adam G Tabák; Markus Jokela; Tasnime N Akbaraly; Eric J Brunner; Mika Kivimäki; Daniel R Witte
Journal:  Lancet       Date:  2009-06-08       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.